Bristol Myers Squibb Co (BMY) Stock Price & Analysis
Bristol Myers Squibb Co (BMY) rose 1.64% to USD 56.48 as of June 9, 2026 at 22:33 UTC, according to Nexqual real-time market data.
BMY last closed at USD 55.57; the session ranged USD 55.27–56.53 on volume of 8,831,192 shares. Market capitalization is $115.34B, with a 52-week range of USD 42.52–62.89 (NYQ). Source: Nexqual, June 9, 2026 at 22:33 UTC.
Key Statistics (as of June 9, 2026 at 22:33 UTC)
| Price | USD 56.48 |
|---|---|
| Change | ▲ 1.64% (up) |
| Previous Close | USD 55.57 |
| Open | USD 56.03 |
| Day Range | USD 55.27 – 56.53 |
| 52-Week Range | USD 42.52 – 62.89 |
| Volume | 8,831,192 shares |
| Market Cap | $115.34B |
| Exchange | NYQ |
Technical Analysis (BMY)
Nexqual's technical model rates BMY "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:33 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.76 (neutral) |
| vs SMA50 | Below (USD 57.9) |
| MACD | -0.51 (negative) |
Analyst Ratings (BMY)
Wall Street analysts rate BMY "Hold" based on 25 analysts, with a mean price target of USD 63.08 (range USD 40–75), per Nexqual as of June 9, 2026 at 22:33 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 63.08 |
| High Target | USD 75 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 10 / 18 / 1 |
Earnings (BMY)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.61 |
| Revenue Estimate | $11.70B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.58 vs est 1.42 ▲ beat |
| 2025-12-31 | USD 1.26 vs est 1.2 ▲ beat |
| 2025-09-30 | USD 1.63 vs est 1.52 ▲ beat |
| 2025-06-30 | USD 1.46 vs est 1.1 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financials & Fundamentals (BMY)
| Total Revenue | $48.48B |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +71.98% |
| Operating Margin | +33.04% |
| Profit Margin | +15.01% |
| ROE | +38.73% |
| Debt / Equity | 230.97 |
| Current Ratio | 1.42 |
| Total Cash | $10.49B |
| Total Debt | $46.43B |
| Free Cash Flow | $9.85B |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financial Health Score (BMY)
Nexqual rates Bristol Myers Squibb Co's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:33 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 33% |
| Balance Sheet | Weak — $10.5B cash vs $46.4B debt |
| Cash Flow | Strong — FCF $9.85B, 20% margin |
| Efficiency | Strong — ROE 39%, ROA 10.7% |
Ownership (BMY)
| Insider Ownership | +0.08% |
|---|---|
| Institutional Ownership | +83.79% |
| Shares Outstanding | 2.04B |
| Float | 2.04B |
| Short % of Float | +1.80% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Leadership (BMY)
Bristol Myers Squibb Co is led by Christopher S. Boerner (age 54), CEO & Chairman, per Nexqual as of June 9, 2026 at 22:33 UTC.
| CEO & Chairman | Christopher S. Boerner (age 54) |
|---|---|
| Executive VP & CFO | David V. Elkins (age 57) |
Major Backers & Investors (BMY)
Notable institutional backers of Bristol Myers Squibb Co include JPMorgan, Charles Schwab Investment Management, Inc., Charles Schwab, according to Nexqual as of June 9, 2026 at 22:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 4.53% |
| Charles Schwab Investment Management, Inc. | 2.99% |
| Charles Schwab | 2.89% |
| Bank of America Corporation | 1.6% |
| AQR Capital Management, LLC | 1.45% |
| Morgan Stanley | 1.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.62% |
| BlackRock | 9.7% |
| State Street | 6.02% |
| Geode Capital | 2.71% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
From Bristol Myers Squibb Co's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
- It offers products for oncology, hematology, immunology, cardiovascular, neuroscience.
- The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM.
- It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRK | Merck & Company, Inc. | USD 119.6 | ▼ 0.99% |
| ABT | Abbott Laboratories | USD 91.25 | ▲ 0.2% |
| LLY | Eli Lilly and Company | USD 1,144.68 | ▲ 1.17% |
| ABBV | AbbVie Inc. | USD 225.42 | ▼ 0.8% |
| AMGN | Amgen Inc. | USD 344.57 | ▼ 1.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:33 UTC. This page is informational and not investment advice.